405 related articles for article (PubMed ID: 25557211)
21. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
[TBL] [Abstract][Full Text] [Related]
22. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
23. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
24. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
26. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
27. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
Kapp A; Papp K; Bingham A; Fölster-Holst R; Ortonne JP; Potter PC; Gulliver W; Paul C; Molloy S; Barbier N; Thurston M; de Prost Y;
J Allergy Clin Immunol; 2002 Aug; 110(2):277-84. PubMed ID: 12170269
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
29. Pimecrolimus 1% cream (Elidel) for atopic dermatitis.
Bernard LA; Bergman JN; Eichenfield LF
Skin Therapy Lett; 2002 Apr; 7(4):1-3. PubMed ID: 12097994
[TBL] [Abstract][Full Text] [Related]
30. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.
Lakhanpaul M; Davies T; Allen BR; Schneider D
Exp Dermatol; 2006 Feb; 15(2):138-41. PubMed ID: 16433686
[TBL] [Abstract][Full Text] [Related]
31. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
de Bruin-Weller MS; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
33. Position statement: topical calcineurin inhibitors in atopic dermatitis.
Remitz A; De Pità O; Mota A; Serra-Baldrich E; Vakirlis E; Kapp A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2074-2082. PubMed ID: 30288799
[TBL] [Abstract][Full Text] [Related]
34. Pimecrolimus: a review of pre-clinical and clinical data.
Graham-Brown RA; Grassberger M
Int J Clin Pract; 2003 May; 57(4):319-27. PubMed ID: 12800465
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].
Gliński W; Kruszewski J; Silny W; Kurzawa R; Czarnecka-Operacz M; Baran E; Szepietowski J;
Pol Merkur Lekarski; 2004; 17 Suppl 3():3-15. PubMed ID: 15688665
[TBL] [Abstract][Full Text] [Related]
36. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
37. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
38. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
Carr WW
Paediatr Drugs; 2013 Aug; 15(4):303-10. PubMed ID: 23549982
[TBL] [Abstract][Full Text] [Related]
39. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
[TBL] [Abstract][Full Text] [Related]
40. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.
Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C;
Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
